

Supplementary Information

Table S1. Copy number variation (CNV) regions observed in 43 fresh frozen tumour tissue samples from 23 patients. Regions of CNV are associated to patients' PSA recurrence status with Fishers exact test. PSA recurrence information was not obtained from 3 patients. Association is considered significant at $p < 0.05$.

Copy Number Variation Regions	CNV Event	Tumours ($n = 43$)	Patients ($n = 23$)	Patients with PSA Recurrence ($n = 9$)	Patients with no PSA Recurrence ($n = 11$)	p -Value	Level of Significance
22q11.1	gain	16	10	5	4	0.65341748	n
16p12.1	gain	13	12	5	5	1	n
15q22.31	gain	11	8	2	5	0.374226006	n
9q21.11	gain	10	9	3	5	0.66992141	n
8q21.11	gain	7	6	1	3	0.591331269	n
8q22.3	gain	7	7	4	2	0.335913313	n
8q24.13	gain	6	5	2	2	1	n
11p15.5	gain	5	4	2	2	1	n
12q12	gain	5	5	3	1	0.284829721	n
12q21.2	gain	5	4	2	1	0.565789474	n
19q13.43	gain	5	4	1	2	1	n
3p14.1	gain	5	5	2	2	1	n
7p11.2	gain	5	4	1	2	1	n
7p14.1	gain	5	4	2	1	0.565789474	n
7q11.21	gain	5	4	2	1	0.565789474	n
7q33	gain	5	4	2	1	0.565789474	n
8q22.1	gain	5	5	2	2	1	n
8q24.21	gain	5	5	2	2	1	n
2q11.2	gain	5	3	1	2	1	n
7q35	gain	5	4	2	1	0.565789474	n
8p21.2	loss	21	15	7	6	0.374226006	n
8p21.3	loss	21	15	6	7	1	n
8p21.2–8p21.1	loss	19	14	6	6	0.66992141	n

Table S1. *Cont.*

Copy Number Variation Regions	CNV Event	Tumours (<i>n</i> = 43)	Patients (<i>n</i> = 23)	Patients with PSA Recurrence (<i>n</i> = 9)	Patients with no PSA Recurrence (<i>n</i> = 11)	<i>p</i> -Value	Level of Significance
8p21.3–8p21.2	loss	18	14	5	7	1	n
8p23.1–8p22	loss	15	12	5	5	1	n
18q11.2	loss	14	10	4	5	1	n
16q24.1	loss	14	11	5	5	1	n
8p11.22–8p11.21	loss	13	11	5	5	1	n
10q23.31	loss	13	11	7	3	0.069778519	n
21q22.2	loss	13	11	6	5	0.405858538	n
13q13.1	loss	13	10	3	5	0.66992141	n
16q24.2	loss	13	10	5	4	0.65341748	n
16q24.3	loss	12	9	5	4	0.65341748	n
21q22.2–21q22.3	loss	12	10	6	4	0.369849964	n
16q23.2	loss	12	9	5	4	0.65341748	n
16q23.3–16q24.1	loss	12	10	5	4	0.65341748	n
16q24.2–16q24.3	loss	12	9	5	4	0.65341748	n
8p12–8p11.23	loss	11	10	4	5	1	n
18q12.2	loss	11	7	3	3	1	n
10q23.2	loss	11	9	5	2	0.159674923	n
13q14.13	loss	11	8	3	3	1	n
13q14.2	loss	11	7	3	4	1	n
13q33.1	loss	11	7	3	4	1	n
10q23.2–10q23.31	loss	10	8	6	1	0.016640867	*
13q21.33	loss	10	7	2	4	0.642414861	n
16q23.1–16q23.2	loss	10	8	4	4	1	n
15q12	loss	9	9	4	5	1	n
13q14.12–13q14.13	loss	9	7	3	2	0.616873065	n
13q14.13–13q14.2	loss	9	6	2	3	1	n
16q22.1	loss	9	8	3	3	1	n

Table S1. *Cont.*

Copy Number Variation Regions	CNV Event	Tumours (<i>n</i> = 43)	Patients (<i>n</i> = 23)	Patients with PSA Recurrence (<i>n</i> = 9)	Patients with no PSA Recurrence (<i>n</i> = 11)	<i>p</i> -Value	Level of Significance
17p13.2	loss	9	7	3	2	0.616873065	n
13q32.1	loss	8	5	2	3	1	n
18q21.2	loss	8	5	1	4	0.318885449	n
13q14.11–13q14.12	loss	8	6	3	2	0.616873065	n
13q14.3	loss	8	6	3	3	1	n
13q22.2	loss	8	6	3	3	1	n
17p13.2–17p13.1	loss	8	6	3	1	0.284829721	n
6q14.1–6q14.2	loss	8	5	1	3	0.591331269	n
6q14.2–6q14.3	loss	8	5	1	3	0.591331269	n
6q16.2–6q16.3	loss	8	5	1	3	0.591331269	n
18q12.3	loss	7	4	1	3	0.591331269	n
17q21.31	loss	7	5	4	1	0.127321981	n
13q14.2–13q14.3	loss	7	5	3	2	0.616873065	n
13q21.1	loss	7	5	2	2	1	n
13q22.2–13q22.3	loss	7	5	2	3	1	n
13q31.1	loss	7	5	2	2	1	n
20q13.2	loss	7	6	2	1	0.565789474	n
20p12.1	loss	6	5	1	2	1	n
12p13.2–12p13.1	loss	6	5	3	1	0.284829721	n
18q12.1	loss	6	3	1	2	1	n
18q12.1–18q12.2	loss	6	3	1	2	1	n
18q12.2–18q12.3	loss	6	3	1	2	1	n
18q22.3	loss	6	5	1	3	0.591331269	n
6q14.3–6q15	loss	6	4	1	2	1	n
10p13	loss	6	5	2	2	1	n
12p13.31–12p13.2	loss	6	5	3	1	0.284829721	n
12q13.11	loss	6	5	2	2	1	n

Table S1. *Cont.*

Copy Number Variation Regions	CNV Event	Tumours (<i>n</i> = 43)	Patients (<i>n</i> = 23)	Patients with PSA Recurrence (<i>n</i> = 9)	Patients with no PSA Recurrence (<i>n</i> = 11)	<i>p</i> -Value	Level of Significance
13q14.3–13q21.1	loss	6	4	2	2	1	n
13q21.1–13q21.2	loss	6	4	2	2	1	n
13q21.2–13q21.31	loss	6	4	2	2	1	n
13q22.3	loss	6	4	2	2	1	n
13q22.3–13q31.1	loss	6	4	2	2	1	n
16q22.2–16q22.3	loss	6	5	3	2	0.616873065	n
17p12	loss	6	5	2	1	0.565789474	n
3p14.2	loss	6	4	1	1	1	n
4q34.3	loss	6	5	1	1	1	n
5q15	loss	6	6	4	1	0.127321981	n
6q15	loss	6	4	1	2	1	n
6q16.1	loss	6	4	1	2	1	n
6q16.1–6q16.2	loss	6	4	1	2	1	n
5q14.3	loss	6	5	2	2	1	n

level of significance: Statistical significance using Fisher's exact test where (n) = not significant and (*) = $p < 0.05$.

Table S2. Information of genes residing on chromosome regions: 10q23.2–10q23.31 and 10q23.31.

Copy Number Region (Loss)	Genes Annotated to Regions	Genomic Position (Start–End)	PSA Recurrence	
			<i>yes (n = 9)</i>	<i>no (n = 11)</i>
10q23.2–10q23.31	PAPSS2	chr. 10: 89351602–89572982	6/9 (66.7%) *	1/11 (9.1%)
10q23.31	ATAD1	chr. 10: 89572982–89604078	6/9 (66.7%) *	1/11 (9.1%)
	KLLN	chr. 10: 89619109–89639105	6/9 (66.7%) *	1/11 (9.1%)
	PTEN	chr. 10: 89639105–89983512	6/9 (66.7%) *	1/11 (9.1%)
	RNLS	chr. 10: 89983512–90132951	7/9 (77.8%) *	1/11 (9.1%)
	LIPJ	chr. 10: 90225365–90352594	7/9 (77.8%)	3/11 (27.3%)
	ANKRD22			
10q23.31	LIPF	chr. 10: 90356851–90637947	6/9 (66.7%) *	1/11 (9.1%)
	LIPK			
	LIPM			
	LIPN			
10q23.31	ACTA2	chr. 10: 90648926–90755496	6/9 (66.7%) *	1/11 (9.1%)
	FAS			
	STAMBPL1			
10q23.31	CH25H	chr. 10: 90954356–91817088	5/9 (55.6%)	0/11
	IFIT1			
	IFIT1B			
	IFIT2			
	IFIT3			
	IFIT5			
	KIF20B			
	LIPA			
	MIR107			
	PANK1			
	SLC16A12			

* Statistical significance using Fisher's exact test, $p < 0.05$.